<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360724</url>
  </required_header>
  <id_info>
    <org_study_id># 4967/6363R</org_study_id>
    <nct_id>NCT00360724</nct_id>
  </id_info>
  <brief_title>Duloxetine for Chronic Depression: a Double-blind Study</brief_title>
  <official_title>Duloxetine for Chronic Depression: a Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying a new antidepressant medicine, duloxetine, for the treatment
      of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by
      the FDA for the treatment of major depression. The investigators are testing whether this
      medicine is also effective for adults with chronic depression (dysthymic disorder or
      dysthymia).

      Chronic depression, lasting two or more years, often causes significant suffering and
      impairment. The investigators study involves a 6 to 10 week double-blind Initial Phase during
      which half of the participants will take the new medication and half will take a placebo (an
      inactive look-alike pill). After the Initial Phase, a 12-week Continuation Phase will begin,
      during which all subjects can be treated with an FDA-approved antidepressant medication.

      Eligible subjects may also receive MRI scans, to help the investigators understand how
      antidepressants work in treating depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 22-week study of the tolerability, dosing, and efficacy of duloxetine in
      chronically depressed outpatients. Participants can have Dysthymic Disorder (Dysthymia), or
      Depression, Not Otherwise Specified (Depression NOS).

      The first 10 weeks (Acute Phase) are double blind, placebo-controlled, and the second 12
      weeks (Continuation Phase) is open-label and all subjects will receive active medication.

      Tests of cytokine functioning will be performed and analyzed for treatment and placebo
      effects.

      In addition, a subset of patients will be enrolled into an Magnetic Resonance Imaging (MRI)
      sub-study, in which a variety of brain imaging techniques (including anatomical MRI,
      functional MRI (fMRI), MR Spectroscopy, and Diffusion Tensor Imaging) will be performed at
      baseline and week 10. Duloxetine responders will have a third MRI performed at week 22.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS) - 24 Total Score</measure>
    <time_frame>Week 10</time_frame>
    <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS) - 24 Total Score</measure>
    <time_frame>Baseline</time_frame>
    <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cornell Dysthymia Rating Scale (CDRS)</measure>
    <time_frame>Week 10</time_frame>
    <description>CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Functioning Scale (GAF)</measure>
    <time_frame>Week 10</time_frame>
    <description>A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Week 10</time_frame>
    <description>Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Improvement(CGI-I)</measure>
    <time_frame>10 weeks</time_frame>
    <description>The Clinical Global Impression - Improvement(CGI-I) is a 7-point scale that rate patient's total improvement whether or not comparing to his/her condition at baseline.
0 = Not assessed
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse Higher score=greatest worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornell Dysthymia Rating Scale (CDRS)</measure>
    <time_frame>Baseline</time_frame>
    <description>CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Functioning Scale (GAF)</measure>
    <time_frame>Baseline</time_frame>
    <description>A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)</measure>
    <time_frame>Baseline</time_frame>
    <description>To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density.</description>
  </other_outcome>
  <other_outcome>
    <measure>Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)</measure>
    <time_frame>Follow up</time_frame>
    <description>To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Dysthymic Disorder</condition>
  <condition>Depressive Disorder NOS</condition>
  <arm_group>
    <arm_group_label>duloxetine (cymbalta)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine (Cymbalta)</intervention_name>
    <description>duloxetine medication up to dose of 120 mg/day</description>
    <arm_group_label>duloxetine (cymbalta)</arm_group_label>
    <arm_group_label>Placebo treatment</arm_group_label>
    <other_name>duloxetine</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20 to 75 years (ages 20 to 60 for MRI sub-study)

          -  diagnosis of dysthymic disorder (chronic depression) or depression NOS

          -  minimum of 2 years duration of current episode of depression

        Exclusion Criteria:

          -  current major depression

          -  diagnoses including delirium, dementia, bipolar disorder, schizophrenia

          -  substance abuse or dependence in the past 6 months

          -  pregnant or nursing women

          -  serious risk of suicide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Hellerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.DepressionNY.com</url>
    <description>Mood Disorders Research Program website</description>
  </link>
  <results_reference>
    <citation>Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.</citation>
    <PMID>22901348</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <results_first_submitted>October 1, 2013</results_first_submitted>
  <results_first_submitted_qc>October 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2015</results_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dysthymia</keyword>
  <keyword>dysthymic disorder</keyword>
  <keyword>chronic depression</keyword>
  <keyword>chronic low-grade depression</keyword>
  <keyword>atypical depression</keyword>
  <keyword>minor depression</keyword>
  <keyword>depression NOS</keyword>
  <keyword>depression</keyword>
  <keyword>depressive disorder</keyword>
  <keyword>mood disorder</keyword>
  <keyword>unipolar depression</keyword>
  <keyword>low-grade depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited by advertisements, website postings, and from the hospital’s telephone referral service. Conducted between August 2006 and December 2011. Potential participants provided informed consent for study participation. A physical examination was performed and blood and urine samples were collected, including urine toxicology.</recruitment_details>
      <pre_assignment_details>For patients on current ineffective psychotropic medication, washout was required, with &gt;=7 days medication-free (&gt;=28 days for fluoxetine). Concurrent sleep medication (zolpidem) was allowed for a maximum of 5 days during the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine (Cymbalta)</title>
          <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo Treatment</title>
          <description>placebo treatment, treatment with matching capsules of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine (Cymbalta)</title>
          <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo Treatment</title>
          <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="11.7"/>
                    <measurement group_id="B2" value="42.1" spread="11.4"/>
                    <measurement group_id="B3" value="41.6" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HDRS) - 24 Total Score</title>
        <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
        <time_frame>Week 10</time_frame>
        <population>Patients for whom post-baseline data was available and scored 2 or less on the suicide item either at baseline or during the course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment, with capsules matching the duloxetine medication</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HDRS) - 24 Total Score</title>
          <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
          <population>Patients for whom post-baseline data was available and scored 2 or less on the suicide item either at baseline or during the course of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="3.6"/>
                    <measurement group_id="O2" value="10" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANOVA was used to compare measures between baseline and week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.003</p_value>
            <method>Repeated Measures ANOVA</method>
            <method_desc>df 1,55</method_desc>
            <param_type>F statistics</param_type>
            <param_value>9.43</param_value>
            <estimate_desc>time X Drug group, f=9.43,df 1,55, p=.003</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HDRS) - 24 Total Score</title>
        <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
        <time_frame>Baseline</time_frame>
        <population>Patients for whom post-baseline data was available and scored 2 or less on the suicide item either at baseline or during the course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment, with capsules matching the duloxetine medication</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HDRS) - 24 Total Score</title>
          <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
          <population>Patients for whom post-baseline data was available and scored 2 or less on the suicide item either at baseline or during the course of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="3.8"/>
                    <measurement group_id="O2" value="14.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cornell Dysthymia Rating Scale (CDRS)</title>
        <description>CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression</description>
        <time_frame>Week 10</time_frame>
        <population>subjects for whom data post baseline were available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Cornell Dysthymia Rating Scale (CDRS)</title>
          <description>CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression</description>
          <population>subjects for whom data post baseline were available</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="9.5"/>
                    <measurement group_id="O2" value="28.5" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANOVA was used to compare measures between baseline and week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Repeated Measures ANOVA</method>
            <method_desc>d.f. 1,55</method_desc>
            <param_type>F statistics</param_type>
            <param_value>8.72</param_value>
            <estimate_desc>Time x Treatment: F=8.72, d.f=1,55, p=0.05</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Functioning Scale (GAF)</title>
        <description>A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information</description>
        <time_frame>Week 10</time_frame>
        <population>subjects for whom post-baseline data were available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Functioning Scale (GAF)</title>
          <description>A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information</description>
          <population>subjects for whom post-baseline data were available</population>
          <units>points on rating scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" spread="20.9"/>
                    <measurement group_id="O2" value="65.7" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANOVA was used to compare measures between baseline and week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Repeated measures ANOVA</method>
            <method_desc>d.f. 1,55</method_desc>
            <param_type>F statistics</param_type>
            <param_value>5.33</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0–9: indicates minimal depression 10–18: indicates mild depression 19–29: indicates moderate depression 30–63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.</description>
        <time_frame>Week 10</time_frame>
        <population>subjects fro whom post-baseline data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0–9: indicates minimal depression 10–18: indicates mild depression 19–29: indicates moderate depression 30–63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.</description>
          <population>subjects fro whom post-baseline data was available</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="7"/>
                    <measurement group_id="O2" value="10.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANOVA was used to compare measures between baseline and week 10.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Repeated measures ANOVA</method>
            <method_desc>d.f.=1,55</method_desc>
            <param_type>F statistics</param_type>
            <param_value>0.26</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions Improvement(CGI-I)</title>
        <description>The Clinical Global Impression - Improvement(CGI-I) is a 7-point scale that rate patient's total improvement whether or not comparing to his/her condition at baseline.
0 = Not assessed
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse Higher score=greatest worsening</description>
        <time_frame>10 weeks</time_frame>
        <population>subjects for whom post-baseline data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions Improvement(CGI-I)</title>
          <description>The Clinical Global Impression - Improvement(CGI-I) is a 7-point scale that rate patient's total improvement whether or not comparing to his/her condition at baseline.
0 = Not assessed
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse Higher score=greatest worsening</description>
          <population>subjects for whom post-baseline data was available</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread=".8"/>
                    <measurement group_id="O2" value="3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cornell Dysthymia Rating Scale (CDRS)</title>
        <description>CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression</description>
        <time_frame>Baseline</time_frame>
        <population>subjects for whom data post baseline were available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Cornell Dysthymia Rating Scale (CDRS)</title>
          <description>CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression</description>
          <population>subjects for whom data post baseline were available</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="8.0"/>
                    <measurement group_id="O2" value="37.4" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0–9: indicates minimal depression 10–18: indicates mild depression 19–29: indicates moderate depression 30–63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.</description>
        <time_frame>Baseline</time_frame>
        <population>subjects for whom post-baseline data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0–9: indicates minimal depression 10–18: indicates mild depression 19–29: indicates moderate depression 30–63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.</description>
          <population>subjects for whom post-baseline data was available</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="5.8"/>
                    <measurement group_id="O2" value="15.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Functioning Scale (GAF)</title>
        <description>A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information</description>
        <time_frame>Baseline</time_frame>
        <population>subjects for whom post-baseline data were available</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Functioning Scale (GAF)</title>
          <description>A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information</description>
          <population>subjects for whom post-baseline data were available</population>
          <units>points on rating scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" spread="5.8"/>
                    <measurement group_id="O2" value="58.3" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)</title>
        <description>To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
Duloxetine (Cymbalta): duloxetine medication up to dose of 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules
Duloxetine (Cymbalta): duloxetine medication up to dose of 120 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)</title>
          <description>To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density.</description>
          <units>percentage of connecting nods</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.08"/>
                    <measurement group_id="O2" value="0.24" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)</title>
        <description>To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density.</description>
        <time_frame>Follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine (Cymbalta)</title>
            <description>Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
Duloxetine (Cymbalta): duloxetine medication up to dose of 120 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>placebo treatment: treatment with placebo capsules that match active medication capsules
Duloxetine (Cymbalta): duloxetine medication up to dose of 120 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Resting-state Functional Connectivity Magnetic Resonance Imaging(fMRI)</title>
          <description>To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density.</description>
          <units>percentage of connecting nods</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.06"/>
                    <measurement group_id="O2" value="0.19" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>patients were treated in study for 22 weeks, including 10 weeks double blind medication vs placebo and 12 weeks open label treatment.</time_frame>
      <desc>All started participants were assessed for Serious Adverse Events, while only completed participants were assessed for Other Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine (Cymbalta)</title>
          <description>Duloxetine medication, ranging from 30 to 120 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo Treatment</title>
          <description>placebo treatment: treatment with placebo capsules that match active medication capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Decreased Sleep</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vivid Dream</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Hellerstein MD</name_or_title>
      <organization>NY State Psychiatric Institute</organization>
      <phone>6467748000</phone>
      <email>hellers@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

